• Nitazoxanide Targets IMPA1-RAGE to Reverse Pulmonary Vascula

  2026-06-22

  This study demonstrates that nitazoxanide reverses pulmonary vascular remodeling in pulmonary hypertension by directly targeting the IMPA1-RAGE signaling axis. The findings reveal a novel mechanism for nitazoxanide in suppressing PASMCs proliferation and metabolism, with significant implications for developing more effective therapies against pulmonary hypertension.

• Linezolid Oxazolidinone Antimicrobial: Workflows & Optimizat

  2026-06-22

  Linezolid empowers researchers to dissect Gram-positive antimicrobial resistance, offering robust workflows for MRSA and VRE investigations. This guide delivers actionable protocols, troubleshooting insights, and highlights innovations for experimental success.

• ETS1 Regulates SENP2/HSPA8/FUNDC1 Axis to Inhibit Mitophagy

  2026-06-21

  This study uncovers how the transcription factor ETS1 mitigates bronchopulmonary dysplasia (BPD) by targeting the SENP2/HSPA8/FUNDC1 axis, thereby inhibiting mitochondrial damage-induced autophagy. The findings provide mechanistic insights into mitophagy regulation in lung injury and highlight potential molecular targets for future autophagy research.

• Dynasore: Benchmark Dynamin GTPase Inhibitor for Endocytosis

  2026-06-20

  Dynasore empowers researchers to dissect dynamin-dependent endocytosis and vesicle trafficking with unmatched precision and reversibility. By enabling real-time inhibition of dynamin GTPase activity, it unlocks advanced workflows in signal transduction, viral entry studies, and disease modeling, setting a new standard for reproducibility.

• Pioglitazone as a PPARγ Agonist: Protocols and Innovations

  2026-06-19

  Pioglitazone, a selective PPARγ agonist, enables precise modulation of macrophage polarization and metabolic pathways in disease models. This article translates recent mechanistic advances and experimental protocols into actionable workflows, troubleshooting tips, and best practices for maximizing reproducibility in metabolic and inflammatory research.

• Penicillin G Sodium: Applied Workflows and Troubleshooting T

  2026-06-19

  Penicillin G Sodium stands apart as a natural penicillin antibiotic, offering precise inhibition of bacterial cell wall biosynthesis for both experimental and translational research. Discover stepwise protocols, nuanced troubleshooting, and integration strategies that leverage APExBIO’s high-purity Penicillin G Sodium to streamline infection control and enhance cell-based assays.

• SB 202190: Applied Protocols for p38 MAP Kinase Inhibitor Re

  2026-06-18

  SB202190 (FHPI) redefines precision in p38 MAP kinase inhibitor workflows, empowering translational research in inflammation and cancer. Discover actionable protocol enhancements, troubleshooting strategies, and advanced use-cases—all grounded in recent breakthroughs and optimized for robust, reproducible results.

• ATRX Loss Sensitizes Glioma to Multi-Target RTK/PDGFR Inhibi

  2026-06-18

  Pladevall-Morera et al. reveal that high-grade glioma cells deficient in ATRX display marked sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. This discovery highlights ATRX status as a meaningful biomarker for optimizing targeted therapies in aggressive glioma models.

• Acridine Orange hydrochloride: Technical Guide for Nucleic A

  2026-06-17

  Acridine Orange hydrochloride enables rapid, differential staining of DNA and RNA, supporting workflows such as cell cycle analysis and apoptosis detection. It should be applied only within nucleic acid staining protocols and is not intended for long-term solution storage or non-cytochemical applications.

• Poly(I:C): A Translational Keystone for Innate Immune Activa

  2026-06-17

  This thought-leadership article explores how Poly(I:C), a synthetic double-stranded RNA analog and Toll-like receptor 3 (TLR3) agonist, empowers translational researchers to interrogate and modulate innate immune pathways. We synthesize mechanistic insights, recent evidence from cancer immunotherapy studies, and practical guidance, positioning APExBIO’s Poly(I:C) as a cornerstone for reliable interferon induction and dendritic cell maturation. Distinct from conventional product guides, we connect foundational pathways to emerging translational strategies, highlight protocol best practices, and critically examine the future of cross-domain application.

• Rapamycin (Sirolimus): Specific mTOR Inhibition and Research

  2026-06-16

  Rapamycin (Sirolimus) is a potent, specific mTOR inhibitor with a sub-nanomolar IC50, widely used for dissecting cell signaling and immunosuppression mechanisms. It modulates AKT/mTOR, ERK, and JAK2/STAT3 pathways, induces apoptosis in lens epithelial cell models, and delays pathology in Leigh syndrome mouse models. APExBIO’s Rapamycin (SKU A8167) offers high purity and robust solubility for precise laboratory protocols.

• Phosphatase Inhibitor Cocktail 2: Preserving Phosphoproteins

  2026-06-16

  Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) from APExBIO empowers researchers to capture true phosphorylation states in complex tissue extracts, including those from metabolic disease models. This article details robust workflows, advanced troubleshooting, and translational insights inspired by recent breakthroughs in autophagy and hepatic steatosis research.

• Berberrubine Chloride: Advanced Mechanistic Insights for Can

  2026-06-15

  Explore how Berberrubine chloride advances cancer and metabolic disease research through its multi-targeted mechanisms. This article offers an in-depth analysis of its enzyme inhibition, assay considerations, and translational value, positioning APExBIO’s Berberrubine chloride as a cornerstone for rigorous preclinical studies.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-06-15

  Wang et al. reveal a novel METTL16-SENP3-LTF signaling axis that confers ferroptosis resistance and promotes tumor growth in hepatocellular carcinoma (HCC). Their work uncovers the epitranscriptomic control of iron metabolism in HCC, highlighting a new therapeutic vulnerability.

• Trelagliptin Succinate Enhances PI-3K/AKT Signaling in Adipo

  2026-06-14

  This study elucidates how trelagliptin succinate improves insulin resistance in adipocytes by upregulating PI-3K/AKT/GLUT4 signaling and modulating adipokine secretion. The findings clarify the molecular mechanism underlying trelagliptin’s action and provide actionable insights for metabolic disease research models.

454 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page